8-K: CyPath Lung Featured in U.S. Medicine Magazine

bioAffinity Technologies' CyPath Lung test is highlighted in U.S. Medicine Magazine for its potential to improve lung cancer detection and reduce costs for the Department of Veterans Affairs.

Summary

• U.S. Medicine Magazine featured CyPath Lung in its pulmonary issue, recognizing its potential to improve lung cancer detection and lower costs for the Department of Veterans Affairs (VA).
• Economic modeling published in the Journal of Health Economics and Outcomes Research (JHEOR) projected savings of nearly $895 million for private payers and $379 million for Medicare if CyPath Lung had been part of the standard of care in 2022 for diagnosing lung cancer in patients with small pulmonary nodules.
• These projected savings are primarily due to reductions in follow-up diagnostic assessments and procedures, minimizing unnecessary interventions and associated risks.
• An earlier clinical study demonstrated CyPath Lung's high diagnostic performance with 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules 20 mm or smaller in high-risk patients.
• Recent case studies reported CyPath Lung detecting lung cancer at curative Stage 1A, even when other diagnostic tools like PET/CT, serum markers, and risk models failed to indicate a higher chance of cancer.
• CyPath Lung utilizes proprietary advanced flow cytometry and artificial intelligence (AI) to identify malignant cell populations in patient sputum, incorporating a fluorescent porphyrin.

Sentiment

Score: 8

Explanation: The filing reports significant positive recognition from a key industry publication, strong clinical performance metrics, and substantial projected cost savings, indicating a very favorable development for the company's product and market positioning.

Positives

• Recognition by U.S. Medicine Magazine, a leading publication for federal healthcare professionals, validates CyPath Lung's potential.
• Projected economic savings of nearly $895 million for private payers and $379 million for Medicare, primarily from reducing unnecessary follow-up procedures.
• High diagnostic performance with 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules (under 20mm).
• Demonstrated ability to detect lung cancer at curative Stage 1A in case studies, outperforming other diagnostic tools.
• Addresses a critical need in veterans' healthcare by efficiently triaging patients with small pulmonary nodules, potentially leading to earlier diagnosis and better outcomes.

Risks

• The ability of CyPath Lung to improve lung cancer detection may not meet expectations.
• CyPath Lung may not effectively help federal medical systems address veterans at higher risk for developing lung cancer.
• Potential cost savings resulting from the use of CyPath Lung may not materialize as projected.
• The benefits of adding CyPath Lung to the standard of care may not be realized.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent SEC filings could materially affect actual results.

Future Outlook

The company believes CyPath Lung has the potential to improve lung cancer detection, help federal medical systems address at-risk veterans, generate cost savings, and provide benefits when added to the standard of care. However, these are forward-looking statements subject to various risks and uncertainties.

Management Comments

• "We are honored that U.S. Medicine recognized both the economic and clinical benefits of CyPath Lung in veterans healthcare."
• "Adding CyPath Lung to the standard of care reduces costs to the federal medical system and provides physicians who care for our veterans with a powerful tool to clarify uncertainty and improve patient outcomes."

Industry Context

The healthcare industry, particularly in oncology and diagnostics, is increasingly focused on early detection, non-invasive methods, and cost-efficiency. The rise in screening for at-risk populations (like veterans) leads to more incidental findings (small pulmonary nodules), creating a demand for better triage tools to avoid unnecessary invasive procedures. CyPath Lung's approach aligns with these trends by offering a non-invasive, AI-powered solution that promises both clinical efficacy and economic benefits, potentially positioning it favorably against traditional, more invasive diagnostic pathways.

Comparison to Industry Standards

• CyPath Lung's reported 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in nodules 20 mm or smaller compares favorably to the challenges faced by practitioners who often have to choose between watchful waiting and invasive diagnostic procedures that may not be necessary for small pulmonary nodules.
• The ability of CyPath Lung to detect lung cancer at curative Stage 1A in case studies, when other diagnostic tools including PET/CT, serum markers, and risk models used with imaging failed, suggests a potential advantage over existing methods for early-stage detection.
• The projected cost savings of nearly $895 million for private payers and $379 million for Medicare, primarily from reductions in follow-up diagnostic assessments and procedures, indicate a significant economic advantage compared to the current standard of care which often involves more expensive and risky interventions.

Stakeholder Impact

• Shareholders: Positive impact due to increased visibility, potential market adoption, and projected cost savings, which could lead to increased revenue and profitability.
• Veterans/Patients: Improved outcomes through earlier and more accurate lung cancer detection, reduced need for invasive procedures, and potentially more favorable prognoses.
• Healthcare Providers (VA, private payers): Access to a powerful diagnostic tool that clarifies uncertainty, improves patient triaging, and offers significant cost reductions.
• Employees: Potential for increased job security and growth opportunities as the company's product gains wider adoption.

Next Steps

• Continue marketing CyPath Lung as a Laboratory Developed Test (LDT) through Precision Pathology Laboratory Services.
• Further integrate CyPath Lung into the standard of care for high-risk patients, particularly within federal medical systems like the VA.

Key Dates

Recommendation

The filing presents highly positive developments for bioAffinity Technologies, including significant validation from U.S. Medicine Magazine, compelling economic projections of substantial cost savings for major healthcare systems, and strong clinical performance data for CyPath Lung. The ability to detect early-stage lung cancer non-invasively, coupled with the potential to reduce healthcare costs, positions the company favorably in a critical market. These factors suggest a strong growth trajectory and potential for increased market penetration, making it an attractive investment.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer detection, veterans healthcare, VA, noninvasive diagnostic, early-stage cancer, pulmonary nodules, AI, flow cytometry, healthcare costs, diagnostic test, biotechnology, medical device, oncology